Correction to Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.

9th Page. The correct version of Figure 10 is shown in this Addition/Correction. 11th Page, Section 3.12.1. Starting with the sixth line of section 3.12.1 and ending with the next-to-last sentence of the section (i.e., from “In the case of HBV infection ...” to “... and HDV RNA in Caucasian patients.165−168”), the text and references should be changed to the following (with reference numbering here referring to the references within this Addition/Correction): “In the case of HBV infection, a number of NAPs could reduce duck HBsAg both in vitro and in vivo in PDHs and DHBV infected ducks, respectively. For example, 53 (REP 2055, Figure 10) was shown activities against DHBV infection at a low dose of 1 mg/kg with good tolerability. Further mechanism study in vivo disclosed that the eventual anti-DHBV activity was a post-entry inhibition, but not a direct immunostimulatory effect, even though it brought out antiviral effects during and after DHBV viral entry in vitro. A current clinical active 63 (REP 2139, Figure 10) showed little HBV entry effects in HepaRG cell compared to 53. NAP 63 was currently in phase II clinical trial (NCT02565719) for the treatment of HBV and HBV/HDV coinfection both as a monotherapy or as a combination therapy with IFNs that disclosed a reduction of both HBsAg and HDV RNA in Caucasian patients; however, this may imply the post-entry effects of NAPs were more important for antiviral effects in human.”